Novartis Ag (GB:0K9E)
UK Market

Novartis Stock Analysis & Ratings

GB:0K9E Stock Chart & Stats

Day’s Range$88.48 - $89.23
52-Week Range$0.00 - $0.00
Previous Close$88.52
Average Volume (3M)29.43K
Market Cap$196.24B
P/E RatioN/A
Next EarningsJul 19, 2022
Dividend Yield2.18 (2.44%)
1Y Price TargetN/A
Smart Score9
EPS (TTM)0.00



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Novartis’s price range in the past 12 months?
Novartis lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Novartis’s market cap?
    Novartis’s market cap is $196.24B.
      What is Novartis’s price target?
      Currently, no data Available
      What do analysts say about Novartis?
      Novartis’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
        When is Novartis’s upcoming earnings report date?
        Novartis’s upcoming earnings report date is Jul 19, 2022 which is in 57 days.
          How were Novartis’s earnings last quarter?
          Novartis released its earnings results on Apr 26, 2022. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.453 by $0.007.
            Is Novartis overvalued?
            According to Wall Street analysts Novartis’s price is currently Overvalued.
              Does Novartis pay dividends?
              Novartis pays a Annually dividend of $2.18 which represents an annual dividend yield of 2.44%. Novartis’s last Annually dividend payment was on Mar 17, 2022. Novartis’s upcoming ex-dividend date is Mar 08, 2022
                What is Novartis’s EPS estimate?
                Novartis’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Novartis have?
                Novartis has 2,210,000,000 shares outstanding.
                  What happened to Novartis’s price movement after its last earnings report?
                  Novartis reported an EPS of $1.46 in its last earnings report, beating expectations of $1.453. Following the earnings report the stock price went up 0.224%.
                    Which hedge fund is a major shareholder of Novartis?
                    Among the largest hedge funds holding Novartis’s share is Dodge & Cox. It holds Novartis’s shares valued at 2B.


                      Novartis Stock Analysis

                      Smart Score
                      Price Target
                      No data currently available
                      The Novartis stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Novartis Ag

                      Novartis AG develops, manufactures and sells healthcare products. Its two reporting segments are: Innovative Medicines and Sandoz. The Innovative Medicines business develops and sells patented prescription medicines and is made up of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

                      Similar Stocks
                      Price & Change
                      Roche Holding
                      Abbott Labs

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis